BeyondSpring (NASDAQ:BYSI) Stock Price Down 0.6% – Here’s What Happened

Posted by Patrick Bannon on Mar 27th, 2026

BeyondSpring Inc. (NASDAQ:BYSI – Get Free Report) was down 0.6% during mid-day trading on Friday . The stock traded as low as $1.5450 and last traded at $1.60. Approximately 22,271 shares changed hands during mid-day trading, a decline of 15% from the average daily volume of 26,164 shares. The stock had previously closed at $1.61.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of BeyondSpring in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Read Our Latest Stock Analysis on BYSI

BeyondSpring Stock Down 0.6%

The company has a market cap of $65.79 million, a PE ratio of -10.67 and a beta of 0.56. The business’s 50 day moving average price is $1.52 and its 200-day moving average price is $1.74.

BeyondSpring (NASDAQ:BYSI – Get Free Report) last announced its earnings results on Wednesday, March 25th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.49.

Hedge Funds Weigh In On BeyondSpring

An institutional investor recently bought a new position in BeyondSpring stock. State Street Corp bought a new stake in shares of BeyondSpring Inc. (NASDAQ:BYSI – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned approximately 0.57% of BeyondSpring at the end of the most recent reporting period. 40.29% of the stock is owned by hedge funds and other institutional investors.

BeyondSpring Company Profile

(Get Free Report)

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.